《Table 1 Summary of clinical studies evaluating magnesium use in intracerebral hemorrhage》

《Table 1 Summary of clinical studies evaluating magnesium use in intracerebral hemorrhage》   提示：宽带有限、当前游客访问压缩模式
本系列图表出处文件名：随高清版一同展现
《Magnesium:pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage》


  1. 获取 高清版本忘记账户？点击这里登录
  1. 下载图表忘记账户？点击这里登录
ICH:Intracerebral hemorrhage；mRS:modified Rankin score；NIHSS:National Institutes of Health Stroke Scale；N/A:not available.

The physiological properties of magnesium in ICH are not as well understood as with ischemic stroke models.However，three key properties of magnesium—vasodilation，hemostasis，and reduction of PHE through BBB preservation—may make magnesium therapy a worthwhile future target for improving clinical outcome after ICH.Although two large randomized trials did not demonstrate efficacy of magnesium therapy in ICH，both trials were not designed to optimize therapeutic targets for ICH pathophysiology.In contrast，several recent large retrospective trials have demonstrated associations in ICH between low admission serum magnesium levels and clinical outcome，admission hematoma volume，and hematoma expansion.The results of these studies（Table 1）suggest that with a proper methodology focused on ICH pathophysiology，magnesium may prove to have some clinical benefit in ICH.

图表编号XD0040617700    严禁用于非法目的
绘制时间2019.07.01
作者Jason J.Chang、Rocco Armonda、Nitin Goyal、Adam S.Arthur
绘制单位Department of Critical Care Medicine,MedStar Washington Hospital Center、Department of Neurology,Georgetown University School of Medicine、Department of Neurosurgery,Georgetown University School of Medicine、Department of Neurology,University of Tennessee He
更多格式高清、无水印（增值服务）

相关图表

  1. 《Table 1Clinical characteristics of study patients with COVID-19.》2020.10.01
  2. 《Table 1 Information of primers used in this study》2018.08.01
  3. 《Table 1 Summary of clinical features of hepatoid carcinomas of the pancreas reported in the English language literature》2020.03.26
  4. 《Table 1 Clinical characteristics of the study subjects》2019.04.14
  5. 《Table 1 Summary of primers used in this study》2019.05.20
  6. 《Table 1 Summary of landmark international and Australia coronary artery disease studies》2019.01.18
  7. 《Table 1 Summary of landmark international and Australia coronary artery disease studies》2019.01.18
  8. 《Table 1 Clinical data of patients in this study》2019.03.26
  9. 《Table 2 Description of studies using a clinical assessment strategy to reduce upper gastrointestinal endoscopies》2019.01.14
  10. 《Table 1 Summary of studies reporting reproductive modes of Phenacoccus solenopsis》2019.04.20
  11. 《Table 1 International Classification of Diseases, ninth edition, clinical modification codes used in defining study vari》2019.01.16
  12. 《Table 1 Demographic, anthropometric and clinical characteristics of the study subjects n (%)》2019.01.15
  13. 《Table 1 Clinical characteristics of the study population》2019.06.01
  14. 《Table 2 Clinical characteristics of study participants》2019.03.01
  15. 《Table 1 Demographic and clinical characteristics of the study population》2019.01.18
  16. 《Table 2Summary of study characteristics.》2019.02.15
  17. 《Table 1 Clinical characteristics of the study subjects》2018.08.18
  18. 《Table 1Clinical characteristics of study participants.》2018.10.15
  19. 《Table 1.Summary of the study sites.》2018.03.10
  20. 《表1 本文选取的各降水数据集基本情况Tab.1 Summary of 14 precipitation datasets used in this study》2018.11.28

随机翻阅

《表7《人民日报》样本中不同体裁文本的篇数及比例》 《表3 不同压迫程度对MF、RMS的影响情况》 《表2 主要变量的描述性统计》 《表3 两组患者Child-Pugh评分和满意度比较》 《表2 中草药添加剂对中华鳖幼鳖抗氧化功能的影响》 《表1 两组患者在护理前后的七种情志出现情况》 《表3 两组治疗效果对比[n(%)]》 《表4 不同胚胎移植类型ART患者E2制剂超说明书用药情况[张 (%) ]Tab 4 Off-label use of E2preparations in ART pa-tients of different embryo transplan》 《表1 两组临床疗效对比[n (%) ]》 《表2 地震波参数：混合连接自复位框架结构抗震性能研究》